کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2484219 | 1114303 | 2016 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Three-Dimensional Printing of Carbamazepine Sustained-Release Scaffold
ترجمه فارسی عنوان
چاپ سه بعدی کاربامازپین داربست پایدار انتشار
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
AEDCIJDODRP-HPLCABS3DPSDSPBSZero-order release - آزادی صفرSustained release - آزادی پایدارacrylonitrile butadiene styrene - استریل بوتادین آکریلونیتریلUltraviolet - اشعه فرابنفشanti-epileptic drug - داروهای ضد صرعCNS - دستگاه عصبی مرکزیsodium dodecyl sulfate - سدیم دودسیل سولفاتcentral nervous system - سیستم عصبی مرکزیPhosphate buffered saline - فسفات بافر شورFused Deposition Modeling - مدل سازی رسوبدهThree-dimensional printing - چاپ سه بعدیcarbamazepine - کاربامازپینDrop on demand - کاهش تقاضاReverse-phase high performance liquid chromatography - کروماتوگرافی مایع با کارایی معکوس فاز
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
اکتشاف دارویی
چکیده انگلیسی
Carbamazepine is the first-line anti-epileptic drug for focal seizures and generalized tonic-clonic seizures. Although sustained-release formulations exist, an initial burst of drug release is still present and this results in side effects. Zero-order release formulations reduce fluctuations in serum drug concentrations, thereby reducing side effects. Three-dimensional printing can potentially fabricate zero-order release formulations with complex geometries. 3D printed scaffolds with varying hole positions (side and top/bottom), number of holes (4, 8, and 12), and hole diameters (1, 1.5, and 2 mm) were designed. Dissolution tests and high performance liquid chromatography analysis were conducted. Good correlations in the linear release profiles of all carbamazepine-containing scaffolds with side holes (R2 of at least 0.91) were observed. Increasing the hole diameters (1, 1.5, and 2 mm) resulted in increased rate of drug release in the scaffolds with 4 holes (0.0048, 0.0065, and 0.0074 mg/min) and 12 holes (0.0021, 0.0050, and 0.0092 mg/min), and the initial amount of carbamazepine released in the scaffolds with 8 holes (0.4348, 0.7246, and 1.0246 mg) and 12 holes (0.1995, 0.8598, and 1.4366 mg). The ultimate goal of this research is to improve the compliance of patients through a dosage form that provides a zero-order drug release profile for anti-epileptic drugs, so as to achieve therapeutic doses and minimize side effects.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Pharmaceutical Sciences - Volume 105, Issue 7, July 2016, Pages 2155-2163
Journal: Journal of Pharmaceutical Sciences - Volume 105, Issue 7, July 2016, Pages 2155-2163
نویسندگان
Seng Han Lim, Samuel Ming Yuan Chia, Lifeng Kang, Kevin Yi-Lwern Yap,